Category:

V2X (VVX) – Two Contract Expansions

Posted on by cpereira@noblefcm.com


Monday, April 29, 2024

For more than 70 years, Vectrus has provided critical mission support for our customers’ toughest operational challenges. As a high-performing organization with exceptional talent, deep domain knowledge, a history of long-term customer relationships, and groundbreaking technical expertise, we deliver innovative, mission-matched solutions for our military and government customers worldwide. Whether it’s base operations support, supply chain and logistics, IT mission support, engineering and digital integration, security, or maintenance, repair and overhaul, our customers count on us for on-target solutions that increase efficiency, reduce costs, improve readiness, and strengthen national security. Vectrus is headquartered in Colorado Springs, Colo., and includes about 8,100 employees spanning 205 locations in 28 countries. In 2021, Vectrus generated sales of $1.8 billion. For more information, visit the company’s website at www.vectrus.com or connect with Vectrus on Facebook, Twitter, and LinkedIn.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Contract Expansions. V2X recently saw two major ID/IQ contracts receive major expansions by the federal contracting authorities. These expansions provide additional growth opportunities, in our view, for V2X which will benefit operational results going forward.

MAC III. V2X was once again named to the U.S. Navy’s Global Contingency Services Multiple Award Contract (MAC) III. The contract is valued at up to $2 billion with an expected completion date of September 2032. Under the previous $900 million MAC II vehicle, V2X received nearly $300 million in awarded task orders. Under MAC III, the Company will continue to provide critical facility support services for a wide range of scenarios.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Fed’s Preferred Inflation Gauge Stubbornly High at 2.8%, Locking in Higher Rates

Posted on by slightbourne@noblecapitalmarkets.com

Inflation in the United States showed alarmingly little signs of cooling in March, according to the latest data on the Federal Reserve’s preferred price gauge released Friday. The stubbornly elevated readings essentially guarantee the U.S. central bank will need to keep interest rates higher for longer to fully constrain persistent price pressures.

The core personal consumption expenditures (PCE) price index, which strips out volatile food and energy costs, rose 2.8% in March from a year earlier, the Commerce Department reported. This matched February’s annual increase and exceeded economists’ expectations of 2.7%.

On a month-over-month basis, the core PCE climbed 0.3% in March, in line with projections. The headline PCE price index including food and energy costs also rose 0.3% for the month and was up 2.7% annually.

The data highlights the challenges the Fed is facing in its battle to bring inflation back down to its 2% target after it surged to multi-decade highs last year on supply shocks, robust demand and pandemic-driven disruptions. Price pressures have proved remarkably persistent, defying the central bank’s aggressive interest rate hiking campaign that kicked off in March 2022.

“Inflation reports released this morning were not as hot as feared, but investors should not get overly anchored to the idea that inflation has been completely cured and the Fed will be cutting interest rates in the near-term,” said George Mateyo, chief investment officer at Key Private Bank. “The prospects of rate cuts remain, but they are not assured.”

The fresh PCE readings follow worse-than-expected inflation figures in Thursday’s GDP report that revealed the personal consumption expenditures price index surged at a 3.4% annualized rate in the first quarter. That was well above the 2.7% forecast and offset a decent 1.6% rise in economic growth over the same period.

The persistent inflation pressures backed bets that the Fed will likely leave interest rates unchanged at the current 4.75%-5% range at its next couple of meetings in June and July. According to the CME Group’s FedWatch tool, traders now see around a 44% probability that the central bank could implement two quarter-point rate cuts by the end of 2023.

However, most analysts agree that the Fed would need to see clear signs that consistently high inflation is beginning to dent the still-robust labor market before feeling confident about pivoting to an easing cycle. Policymakers want to avoid making the same mistake of prematurely loosening monetary policy like they did in the 1970s, which allowed inflation to become deeply entrenched.

For investors, the path forward for markets hinges on whether the Fed can achieve a so-called “soft landing” by getting inflation under control without sparking a severe recession. Equity traders largely looked past Friday’s inflation data, with futures pointing to a higher open on Wall Street. But Treasury yields edged lower as traders increased bets on the Fed ultimately reversing course next year.

Still, the latest PCE figures underscore the Fed’s dilemma and the likelihood that interest rates will need to remain restrictive for some time to prevent inflation from becoming unmoored. That raises the risks of overtightening and potential economic turbulence ahead as the full impact of the most aggressive tightening cycle since the 1980s hits home.

Incyte Shells Out $750M for Escient’s Immunology Assets

Posted on by slightbourne@noblecapitalmarkets.com

In a move that further solidifies its position in the inflammatory disease space, Incyte Corporation has agreed to acquire Escient Pharmaceuticals for $750 million. The deal, announced on Tuesday, will add two promising immunology and inflammation candidates to Incyte’s pipeline, complementing its existing dermatology portfolio.

The star assets in the acquisition are EP262 and EP547, both of which have shown promising early results in clinical trials. EP262, the more advanced of the two, is currently being evaluated for the treatment of various inflammatory skin conditions, including atopic dermatitis, psoriasis, and vitiligo. Preclinical data has demonstrated EP262’s ability to improve atopic dermatitis-like lesions and reduce inflammation, making it a potentially valuable addition to Incyte’s dermatology lineup.

EP547, while in an earlier stage of development, is being studied for the treatment of itching associated with kidney and liver diseases – a condition known as pruritus, which can significantly impact a patient’s quality of life. With two phase 1 trials currently underway, EP547 could address a significant unmet need in these patient populations.

“EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases and additional potential launch opportunities starting in 2029,” said Hervé Hoppenot, Incyte’s CEO.

For Incyte, the acquisition of Escient Pharmaceuticals represents a strategic move to strengthen its position in the lucrative dermatology market. The company already has an approved JAK1/JAK2 inhibitor cream, Opzelura, which is indicated for atopic dermatitis and vitiligo. With EP262 and additional pipeline candidates, Incyte aims to expand its offerings and capture a larger share of the growing inflammatory skin disease market.

The deal also follows Incyte’s recent acquisition of the cancer drug Monjuvi from MorphoSys, further demonstrating the company’s commitment to bolstering its portfolio through strategic partnerships and acquisitions.

Escient Pharmaceuticals, a relatively young company founded in 2018, had already attracted significant investor interest, raising over $200 million in private financing rounds from the likes of Sanofi. The company’s promising early-stage pipeline and expertise in inflammatory diseases likely made it an attractive target for Incyte.

The transaction, which is expected to close in the third quarter of 2024, will provide Incyte with a diverse range of assets spanning multiple inflammatory and immunological indications. As the company continues to expand its offerings, it remains well-positioned to capitalize on the growing demand for innovative treatments in these therapeutic areas.

Take a moment to take a look at Noble Capital Markets’ Senior Research Analyst Robert LeBoyer’s coverage list.

Release – ACCO Brands Corporation Declares Quarterly Dividend

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ACCO

04/26/2024

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its board of directors has declared a quarterly cash dividend of $0.075 per share. The dividend will be paid on June 12, 2024, to stockholders of record as of the close of business on May 17, 2024.

“This is the Company’s 26th quarterly cash dividend since it began paying dividends in 2018. The Company’s dividend has become an important part of our capital allocation strategy, and we remain committed to supporting our quarterly dividend with our robust free cash flow. At the current stock price, on an annualized basis, our shareholders are receiving a 6% yield on their investment,” said Tom Tedford, President, and Chief Executive Officer of ACCO Brands.

About ACCO Brands Corporation

ACCO Brands, the Home of Great Brands Built by Great People, designs, manufactures and markets consumer and end-user products that help people work, learn and play. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

Chris McGinnis

Investor Relations

(847) 796-4320

Kori Reed

Media Relations

(224) 501-0406

Source: ACCO Brands Corporation

Release – Ocugen To Present On Modifier Gene Therapy Platform At Association For Research In Vision And Ophthalmology 2024 Annual Meeting

Posted on by aweinsoff@channelchek.com

Research News and Market Data on OCGN

April 26, 2024

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.

“With three gene therapies to treat blindness diseases currently in the clinic, now is an exciting time for Ocugen and the patients who can potentially benefit from our first-in-class modifier gene therapy platform,” said Dr. Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen. “We look forward to sharing more about the scientific foundation of our programs and providing clinical updates with industry leaders during ARVO.”

Ocugen’s presence at ARVO 2024 includes:

Paper Session (oral presentation)

Title: OCU400 Nuclear Hormone Receptor-Based Gene Modifier Therapy: Safety and Efficacy from Phase 1/2 Clinical Trial for Retinitis Pigmentosa Associated with NR2E3 and RHO Mutations

Authors: Byron L. Lam, Arun K. Upadhyay, Shankar Musunuri, Murthy Chavali, Sahar Matloob, Nalin Mehta, David G. Birch, Paul Yang, Benjamin Bakall, Nieraj Jain, Jose S. Pulido, Borooah Shyamanga

Presenter: Byron Lam, MD, Professor of Ophthalmology, Dr. Mark J. Daily Endowed Chair, University of Miami
Presentation Number: 406
Location: Seattle Convention Center, Arch Building, Room 612
Date: Sunday, May 5, 2024
Time: 1:45-2 p.m. (PT)

Exhibitor Presentations

Title: OCU400—A Gene Agnostic Modifier Gene Therapy for the Treatment of Retinitis Pigmentosa (Phase 1/2 Clinical Study Results and Phase 3 liMeliGhT Study Design) 
Presenter: Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen
Location: Show Floor, Educational Lounge, Booth #4921
Date: Monday, May 6, 2024
Time: 1 p.m. (PT)

Title: OCU410 Gene Therapy—Multifactorial Therapeutic Intervention for Dry Age-Related Macular Degeneration 
Presenter: Huma Qamar, MD, MPH, Chief Medical Officer, Ocugen
Location: Show Floor, Educational Lounge, Booth #4921
Date: Tuesday, May 7, 2024
Time: 2 p.m. (PT)

Title: Nuclear Hormone Receptor RORA as a Novel Modifier Approach for Treatment of Stargardt Disease 
Presenter: Murthy Chavali, PhD, Director, Clinical Development, Ocugen
Location: Show Floor, Educational Lounge, Booth #4921
Date: Wednesday, May 8, 2024
Time: 2 p.m. (PT)

Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.

About AAV-hNR2E3 (OCU400)
OCU400 is the Company’s gene-agnostic modifier gene therapy product based on NHR gene, NR2E3. NR2E3 regulates diverse physiological functions within the retina—such as photoreceptor development and maintenance, metabolism, phototransduction, inflammation and cell survival networks. Through its drive functionality, OCU400 resets altered/affected cellular gene networks and establishes homeostasis—a state of balance, which has the potential to improve retinal health and function in patients with retinitis pigmentosa. Between the U.S. and EU, nearly 300,000 people are affected by retinitis pigmentosa. The OCU400 Phase 3 liMeliGhT clinical trial is currently underway and on track to meet the Company’s 2026 BLA and MAA filing targets.

About AAV-hRORA (OCU410/OCU410ST)
AAV-hRORA utilizes an AAV delivery platform for the retinal delivery of the RORA (ROR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role as well as inhibiting the complement system in in-vitro and in-vivo (animal model) studies. These results demonstrate the ability to target multiple pathways linked with dry age-related macular degeneration and Stargardt pathophysiology. Ocugen is developing OCU410 as a one-time gene therapy for the treatment of GA (affecting one million people in the U.S.) and OCU410ST as a one-time gene therapy for the treatment of Stargardt disease (affecting 41,000 people in the U.S.).

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

Release – Entravision Schedules First Quarter 2024 Earnings Release and Conference Call

Posted on by aweinsoff@channelchek.com

Research News and Market Data on EVC

April 25, 2024

Download(opens in new window)

SANTA MONICA, Calif.–(BUSINESS WIRE)– Entravision (NYSE: EVC), a leading global advertising solutions, media and technology company, announced that it will release its first quarter 2024 financial results after market close on Thursday, May 2, 2024. The Company will host a conference call that day at 5:00 p.m. Eastern Time to discuss the first quarter 2024 results.

To access the conference call, please dial (844) 836-8739 (U.S.) or (412) 317-5440 (International) ten minutes prior to the start time. The call will also be available via live webcast on the investor relations portion of the Company’s website located at www.entravision.com.

If you cannot listen to the conference call at its scheduled time, there will be a replay available through Thursday, May 16, 2024, which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 10188233. The webcast will also be archived on the Company’s website.

About Entravision

Entravision (NYSE: EVC) is a global advertising solutions, media and technology company. Over the past three decades, we have strategically evolved into a digital powerhouse, expertly connecting brands to consumers in the U.S., Latin America, Europe and Asia. Our digital segment offers a full suite of end-to-end advertising services across the world. We have commercial partnerships with X Corp. (formerly known as Twitter), TikTok, and Spotify, and marketers can use our Smadex and other platforms to deliver targeted advertising to audiences around the globe. In the U.S., we maintain a diversified portfolio of television and radio stations that target Hispanic audiences and complement our global digital services. Entravision remains the largest affiliate group of the Univision and UniMás television networks. Shares of Entravision Class A Common Stock trade on the NYSE under ticker: EVC. Learn more about our offerings at entravision.com or connect with us on LinkedIn and Facebook.

Christopher T. Young

Chief Financial Officer

Entravision

310-447-3870

ir@entravision.com

Source: Entravision

Release – Conduent Implements I-64 Hampton Roads Express Lanes Tolling System for the Virginia Department of Transportation

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CNDT

APRIL 25, 2024

Conduent to maintain flexible, dynamic pricing and conduct license plate image reviews, helping to improve the flow of traffic and relieve congestion for VDOT

FLORHAM PARK, N.J. — Conduent Transportation, a global provider of smart mobility technology solutions and business unit of Conduent Incorporated (Nasdaq: CNDT), today announced the implementation of an Express Lanes tolling system in Virginia. The system, which went live March 17 on a segment of the I-64 Hampton Roads Express Lanes, was designed by Conduent as part of a 2021 contract from the Virginia Department of Transportation (VDOT).

Conduent will operate and maintain an innovative and completely overhead vehicle classification system, a traffic-responsive dynamic pricing system and an automated license plate recognition system, as well as conduct license plate image reviews for VDOT. These technologies and services are designed to help improve traffic flow and relieve congestion for motorists and passengers.

To enable dynamic pricing, VDOT will use data analytics to determine toll rates based on the volume of traffic during different times of the day, helping reduce overall travel times and enhance predictability and mobility choices for motorists. The lanes remain free for vehicles with two or more occupants using a required E-ZPass Flex transponder.

“It’s exciting to offer our clients the latest innovations in tolling technology that greatly enhance the roadway experience for motorists, from an overhead vehicle classification system to the ease of booth-less electronic payment – all enabling reduced congestion and faster journeys,” said Adam Appleby, President, Transportation Solutions at Conduent. “Our tolling solutions also improve operational efficiency, accuracy and customer service for transportation and tolling authorities. As a leader in road usage charging, Conduent continues to identify new solutions to transform mobility.”

This segment on I-64, located in Chesapeake and Norfolk, is the first of four segments that will be implemented with the new system. The segments will ultimately become a part of a continuous 45-mile Express Lanes network on the corridor. VDOT also has the option under the contract to implement a vehicle occupancy detection system in the future, which would use camera systems and video analytics to identify the number of occupants in a vehicle.

Conduent Transportation is a leading provider of streamlined, high-volume mobility services and solutions, spanning road usage charging and advanced transit systems, that enhance the services provided by transportation agencies to benefit the citizens who use them. For over 50 years, the company has helped clients advance transportation solutions in more than 20 countries.

About Conduent
Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 59,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $100 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

Trademarks
Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts

NEIL FRANZ

Conduent

neil.franz@conduent.com

+1-240-687-0127

GILES GOODBURN

Conduent

ir@conduent.com

+1-203-216-3546

Release – Bitcoin Depot Announces Strategic Investment from Sopris Capital

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTM

April 25, 2024 8:05 AM EDTDownload as PDF

ATLANTA, April 25, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot (“Bitcoin Depot” or the “Company”) (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced a strategic investment from Sopris Capital (“Sopris”), a 20-year-old multi-strategy investment firm. As part of the investment, Sopris Capital has purchased 2,906,976 Class A common shares and is now one of the Company`s largest independent shareholders.

“We are thrilled to own part of a growing, market-leading business at such a compelling valuation. We look forward to collaborating with Bitcoin Depot as they pursue their numerous growth initiatives,” said Andy Paul, Founder and CEO of Sopris Capital.

“We’re excited to welcome Sopris Capital as a strategic investor to help accelerate our growth,” said Bitcoin Depot CEO Brandon Mintz. “With their extensive network of valuable relationships and experience in the cryptocurrency space, Sopris Capital is a fantastic fit for us. Most importantly, they understand our mission and our value proposition.”

In March of this year Sopris Capital purchased 50 kiosks to become a partner in Bitcoin Depot`s Franchise Program, which allowed Sopris to leverage Bitcoin Depot`s operating expertise and receive a passive income stream from its Bitcoin ATMs.

“The investment reinforces the confidence we have in Bitcoin Depot’s strategy and growth potential, which we believe is not reflected in the current public market valuation given their underlying unit economics and ability to redeploy capital at a high return,” said Sopris Capital Vice President Dan Wedman.

Bitcoin Depot’s products and services provide an intuitive, quick, and convenient process for converting cash into Bitcoin, giving users the ability to access the broader digital financial system, including using their Bitcoin for purposes of making payments, transfers, remittances, online purchases, and investments.

This news marks the latest show of momentum for Bitcoin Depot, which holds the largest market BTM share in North America, with over 7,400 Bitcoin ATM locations. The announcement follows several recent milestones and expansions for the company, including its first partnership with a major grocery chain as well as the advancement of its newly launched profit share program in April 2024. The company also recently surpassed its goal of signing 8,000 BTM locations ahead of schedule to achieve the largest installed fleet of locations in its history and announced expansions into new markets, including Puerto Rico and Australia.

About Bitcoin Depot 
Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with approximately 7,400 kiosk locations as of April 1, 2024. Learn more at www.bitcoindepot.com. 

Cautionary Note Regarding Forward-Looking Statements

This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “priorities,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Contacts: 

Investors  
Cody Slach, Alex Kovtun  
Gateway Group, Inc.  
949-574-3860  
BTM@gateway-grp.com 

Media  
Christina Lockwood, Brenlyn Motlagh, Ryan Deloney  
Gateway Group, Inc. 
949-574-3860  
BTM@gateway-grp.com 

Primary Logo

Source: Bitcoin Depot Inc.

Released April 25, 2024

Release – Harte Hanks to Report First Quarter 2024 Financial Results on May 9, 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on HHS

CHELMSFORD, MA / ACCESSWIRE / April 25, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), a leading global customer experience company focused on bringing companies closer to customers for over 100 years, announced today that the company will release financial results for the first quarter of 2024, the period ended March 31, 2024, on Thursday, May 9, 2024, after the close of the market.

The Company will host a conference call and live webcast to discuss these results at 4:30 p.m. EDT on the same day. Interested parties may access the webcast at https://www.webcaster4.com/Webcast/Page/2810/50446 or access the conference call by dialing 888-506-0062 in the United States or 973-528-0011 from outside the U.S. and using access code 689651.

A replay of the call can also be accessed via phone through May 23, 2024, by dialing (877) 481-4010 from the U.S., or (919) 882-2331 from outside the U.S. The conference call replay passcode is 50446.

About Harte Hanks:

Harte Hanks (NASDAQ:HHS) is a leading global customer experience company whose mission is to partner with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.

Using its unparalleled resources and award-winning talent in the areas of Customer Care, Fulfillment and Logistics, and Marketing Services, Harte Hanks has a proven track record of driving results for some of the world’s premier brands, including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM among others. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific.

For more information, visit hartehanks.com

As used herein, “Harte Hanks” or “the Company” refers to Harte Hanks, Inc. and/or its applicable operating subsidiaries, as the context may require. Harte Hanks’ logo and name are trademarks of Harte Hanks.

Investor Relations Contact:

Rob Fink or Tom Baumann
646.809.4048 / 646.349.6641
FNK IR
HHS@fnkir.com

SOURCE: Harte Hanks, Inc.



View the original press release on accesswire.com

Release – The ODP Corporation to Announce First Quarter 2024 Results Wednesday, May 8, 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ODP

PDF Version

BOCA RATON, Fla.–(BUSINESS WIRE)–Apr. 24, 2024– The ODP Corporation (NASDAQ:ODP) (“ODP,” or the “Company”), a leading provider of business services, products and digital workplace technology solutions to businesses and consumers, will announce first quarter 2024 financial results before the market open on Wednesday, May 8th, 2024. The ODP Corporation will webcast a call with financial analysts and investors that day at 9:00 am Eastern Time which will be accessible to the media and the general public.

To listen to the conference call via webcast, please visit The ODP Corporation’s Investor Relations website at investor.theodpcorp.com. A replay of the webcast will be available approximately two hours following the event. A copy of the earnings press release, supplemental financial disclosures and presentation will also be available on the website.

About The ODP Corporation

The ODP Corporation (NASDAQ:ODP) is a leading provider of products and services through an integrated business-to-business (B2B) distribution platform and omnichannel presence, which includes world-class supply chain and distribution operations, dedicated sales professionals, a B2B digital procurement solution, online presence and a network of Office Depot and OfficeMax retail stores. Through its operating companies Office Depot, LLC; ODP Business Solutions, LLC; Veyer, LLC; and Varis, Inc., The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.

ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Office Depot is a trademark of The Office Club, LLC. OfficeMax is a trademark of OMX, Inc. Veyer is a trademark of Veyer, LLC. Varis is a trademark of Varis, Inc. Grand&Toy is a trademark of Grand & Toy, LLC in Canada. Any other product or company names mentioned herein are the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424694019/en/

Tim Perrott
Investor Relations
561-438-4629
Tim.Perrott@theodpcorp.com

Source: The ODP Corporation

Release – Great Lakes Announces New $150,000,000 Second-Lien Financing Agreement

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GLDD

Apr 24, 2024

PDF Version

HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (NASDAQ: GLDD), the largest provider of dredging services in the United States, announced that it has entered into a $150,000,000 5-year, senior secured second-lien credit agreement (“Second Lien Credit Agreement”) with Guggenheim Credit Funding, LLC, on behalf of one or more clients. The Company borrowed $100,000,000 under the Second Lien Credit Agreement on the Closing Date and has the option to draw an additional $50,000,000 for a period of 12 months following the closing date of the initial loan. The loans under the Second Lien Credit Agreement funded on the Closing Date were used to repay amounts outstanding under the ABL Credit Agreement and to pay fees associated with the transactions and will be used to fund upcoming newbuild payments. The delayed draw portion of the term loans, if funded, will be used to fund future newbuild payments, ongoing working capital and other general corporate purposes.

The Second Lien Credit Agreement contains customary representations and affirmative and negative covenants as well as customary events of default. The obligations under the Second Lien Credit Agreement are secured on a second-priority basis by substantially all of the Company’s assets. Further details on the terms of the Second Lien Credit Agreement can be found in the Company’s Form 8-K for the Second Lien Credit Agreement which will be filed within the next four business days.

Scott Kornblau, Great Lakes’ Senior Vice President, Chief Financial Officer, and Treasurer commented, “The second-lien financing shores up our balance sheet and provides additional liquidity to complete our new build program. The delayed draw feature allows Great Lakes to lock in a commitment for additional long-term capital while giving us the flexibility to pursue financing alternatives, including Title XI. We are confident in our long-term strategy and remain committed to delivering value to our shareholders and maintaining a strong balance sheet.”

Lazard Frères & Co. LLC acted as placement agent and sole financial advisor to the Company in connection with the Second Lien Credit Agreement.

The Company
Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 134-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking” statements as defined in Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (the “SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Great Lakes and its subsidiaries, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. These cautionary statements are being made pursuant to the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. Great Lakes cautions investors that any forward-looking statements made by Great Lakes are not guarantees or indicative of future events.

Although Great Lakes believes that its plans, intentions and expectations reflected in this press release are reasonable, actual events could differ materially. The forward-looking statements contained in this press release are made only as of the date hereof and Great Lakes does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

For further information contact:
Tina Baginskis
Director, Investor Relations
630-574-3024

Billionaire Leon Cooperman Sounds the Alarm on Looming Financial Crisis

Posted on by slightbourne@noblecapitalmarkets.com

In a characteristically blunt assessment, billionaire investor Leon Cooperman painted a grim picture of the current economic landscape during his recent appearance on CNBC’s Squawk Box. The legendary investor, known for his storied career at Goldman Sachs and the success of his hedge fund Omega Advisors, did not mince words as he expressed grave concerns about the state of the nation’s leadership, fiscal policies, and the potential for an impending financial crisis.

Cooperman’s remarks kicked off with a scathing critique of the upcoming presidential election, describing the choices as “bad and worse.” This sentiment underscored his belief in a broader “leadership crisis” within the country, which he believes is exacerbating the already precarious economic situation.

At the forefront of Cooperman’s concerns is the ballooning federal debt and the persistent trade deficit plaguing the nation. “The evils of trade and debt deficit,” as he put it, are a ticking time bomb that could potentially trigger a financial crisis of unprecedented proportions. He emphasized that “deficits matter,” and the current trajectory is unsustainable, warning that the consequences of unchecked borrowing and spending could manifest in the form of higher interest rates, rampant inflation, and a weakened currency.

Cooperman also leveled criticism at the Federal Reserve, giving them a “low grade” for their handling of monetary policy. He lambasted the central bank for keeping interest rates near zero for nearly a decade, only to abruptly raise them by a staggering 500 basis points within a year. This whiplash-inducing policy shift, according to Cooperman, is symptomatic of the Fed’s missteps and lack of foresight.

Despite the stock market hovering near record highs, Cooperman warned of rampant speculation and froth in certain segments of the market. He cited the frenzy surrounding former President Trump’s social media venture and the proliferation of special purpose acquisition companies (SPACs) as examples of speculative excess. Cooperman cautioned that the current market euphoria might be misguided, as there are no clear signs that the Fed’s tightening measures have been sufficiently restrictive to rein in inflation.

Interestingly, Cooperman’s portfolio reflects a defensive posture, with 15% allocated to energy stocks and 20% invested in bonds. However, he expressed concerns about the ongoing lawsuit with Spectrum against the government, which could impact the value of his bond holdings.

In a contrarian move, Cooperman revealed a preference for equities over bonds, defying conventional wisdom that favors fixed-income assets in times of economic uncertainty. This stance underscores his belief that certain sectors and companies may offer better risk-adjusted returns than the bond market, which he views as overvalued.

Cooperman’s dire warnings and contrarian positions serve as a stark reminder of the uncertainties and potential pitfalls facing investors in the current market environment. While his views may be controversial, they underscore the importance of vigilance, risk management, and careful asset allocation in navigating the turbulent waters of the global economy.

As investors and financial professionals grapple with the challenges ahead, Cooperman’s sobering assessments demand careful consideration, even if they challenge conventional wisdom. In the end, his candor and willingness to voice unpopular opinions may prove invaluable in preparing for the potential storms on the horizon.

Travelzoo (TZOO) – An Improved Balance Sheet; Stable Outlook

Posted on by cpereira@noblefcm.com


Thursday, April 25, 2024

Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Mixed Q1 Results. The company reported Q1 revenue of $22.0 million, a modest 1.8% increase over the year earlier results and a significant sequential deceleration from 13.7% in the previous quarter. Adj. EBITDA in the latest quarter was $6.1 million, beating our estimate of $5.8 million by 5.0%, a result of lower marketing spend. 

A year of transition.  In January the company switched to a paid subscription, all new members pay a $40 annual fee, while members who joined prior to January 2024 do not pay a subscription fee until January 2025. Notably, the company plans to increase marketing spend in the coming quarters as it aims to grow the number of paid members, a development we view favorably.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.